[Corrigendum] Use of methylation profiling to identify significant differentially methylated genes in bone marrow mesenchymal stromal cells from acute myeloid leukemia
- Authors:
- Published online on: March 17, 2025 https://doi.org/10.3892/ijmm.2025.5520
- Article Number: 79
-
Copyright : © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article
Int J Mol Med 41: [Related article:] 679-686, 2018; DOI: 10.3892/ijmm.2017.3271
Following the publication of the above article, an interested reader drew to the authors' and the Editor's attention that, given the subject matter of the article, in a few places in the text throughout the paper, 'MIR159' was probably intended to have been written as 'MIR596', and 'miR-159' was probably meant to have been written as 'miR-596'.
The authors have responded to confirm that the interested reader was correct in their assessment; this paper discusses the role of miR-596 in the context of acute myeloid leukemia (AML) and its potential as a biomarker, and this error appears to have occurred during the final stages of manuscript preparation. Therefore, the following corrections to the text of this article should be noted:
In the final sentence of the Abstract on p. 679, 'miR-596' should have been written, rather than 'miR-159'. The corrected sentence should read as follows: 'Furthermore, the aberrantly hypermethylated miR-596-encoding gene MIR596 may be a potential biomarker of AML.'
In the Discussion, all instances where 'miR-159' and 'MIR159' were mentioned should be corrected to 'miR-596' and 'MIR596', respectively. The sentences concerned should have read as follows (p. 685, right-hand column, line 9): 'Thus, it was suggested that the hypermethylation of miR-596 may be associated with its transcriptional regulation. It was also inferred that miR-596 methylation in BM-MSCs may be a biomarker or prognostic factor for patients with AML. However, the significance of the methylation of miR-596 demands further investigation." In addition, the sentence starting on p. 685, right-hand column, second paragraph, line 5, should have read as follows: 'Furthermore, the aberrant hypermethylated miR-596-encoding gene MIR596 may be a potential biomarker of AML.'
All the authors agree with the publication of this corrigendum; furthermore, they also apologize to the readership of the journal for any inconvenience caused.
